KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

被引：0

作者：

Wakelee, Heather A.

Liberman, Moishe

Kato, Terufumi

Tsuboi, Masahiro

Lee, Se-Hoon

He, Jie

Gao, Shugeng

Chen, Ke-Neng

Dooms, Christophe Alfons

Majem, Margarita

Eigendorff, Ekkehard

Martinengo, Gaston Lucas

Bylicki, Olivier

Rodriguez-Abreu, Delvys

Chaft, Jamie E.

Novello, Silvia

Yang, Jing

Keller, Steven M.

Samkari, Ayman

Spicer, Jonathan

机构：

[1] Stanford Univ, Stanford Canc Inst, Div Oncol, Dept Med, Stanford, CA USA

[2] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[3] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Sungkyunkwan Univ, Div Hematol Oncol, Dept Internal Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[6] Chinese Acad Med Sci & Peking, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China

[7] Chinese Acad Med Sci & Pek, Dept Thorac Surg, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr, Beijing, Peoples R China

[8] Beijing Canc Hosp, Beijing, Peoples R China

[9] Univ Hosp Leuven, Leuven, Belgium

[10] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[11] Zentralklin Bad Berka GmbH, Bad Berka, Germany

[12] Sanatorio Parque, Santa Fe, Argentina

[13] HIA SAINTE ANNE, Toulon, France

[14] Complejo Hosp Univ Insular Materno Infantil, Las Palmas Gran Canaria, Spain

[15] Mem Sloan Kettering Canc Ctr, New York, NY USA

[16] Univ Turin, AOU San Luigi Orbassano, Turin, Italy

[17] Merck & Co Inc, Rahway, NJ USA

[18] Merck & Co Inc, Kenilworth, NJ USA

[19] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA100

引用

页数：1

共 50 条

[31] KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Shapira-Frommer, Ronnie
Alexandre, Jerome
Monk, Bradley
Fehm, Tanja N.
Colombo, Nicoletta
Caceres, Maria V.
Hasegawa, Kosei
Dubot, Coraline
Li, Jerry Jing
Stein, Karen
Keefe, Stephen Michael
Tewari, Krishnansu Sujata
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[32] CANOPY-1: Phase 3 Study of Canakinumab/Placebo plus Pembrolizumab plus Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Pts
Felip, E.
Castro, G.
Greystoke, A.
Solomon, B.
Tan, D.
Passos, V.
Deudon, S.
Louveau, A.
Johnson, B.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S645 - S645
[33] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Rha, Sun Young
Oh, Do-Youn
Yanez, Patricio
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Rivera, Fernando
Alves, Gustavo Vasconcelos
Garrido, Marcelo
Shiu, Kai-Keen
Fernandez, Manuel Gonzalez
Li, Jin
Lowery, Maeve A.
Cil, Timucin
Cruz, Felipe Melo
Qin, Shukui
Luo, Suxia
Pan, Hongming
Wainberg, Zev A.
Yin, Lina
Bordia, Sonal
Bhagia, Pooja
Wyrwicz, Lucjan S.
LANCET ONCOLOGY, 2023, 24 (11): : 1181 - 1195
[34] Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
Cortes, Javier
Cescon, David W.
Rugo, Hope S.
Nowecki, Zbigniew
Im, Seock-Ah
Yusof, Mastura Md
Gallardo, Carlos
Lipatov, Oleg
Barrios, Carlos Henrique
Perez-Garcia, Jose
Iwata, Hiroji
Masuda, Norikazu
Otero, Marco Torregroza
Gokmen, Erhan
Loi, Sherene
Guo, Zifang
Zhou, Xuan
Karantza, Vassiliki
Pan, Wilbur
Schmid, Peter
CANCER RESEARCH, 2022, 82 (04)
[35] KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Tabernero, J.
Bang, Y.
Van Cutsem, E.
Fuchs, C.
Janjigian, Y.
Bhagia, P.
Li, K.
Adelberg, D.
Qin, S.
ANNALS OF ONCOLOGY, 2020, 31 : S101 - S102
[36] Phase 3 Study of Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+NSCLC
Mok, Tony
Wu, Yi-Long
Sadowski, Sara
Zhang, Jin
Rangwala, Reshma
Lopes, Gilberto De Lima
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S554 - S554
[37] The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy
Moehler, M.
Enzinger, P.
Bennouna, J.
Doi, T.
Shen, L.
Kato, K.
Adenis, A.
Mamon, H.
Fu, X.
Cho, B.
Desai, A.
Bhagia, P.
Shih, C.
Shah, M.
ANNALS OF ONCOLOGY, 2020, 31 : S100 - S100
[38] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
Cortes, Javier
Guo, Zifang
Karantza, Vassiliki
Aktan, Gursel
CANCER RESEARCH, 2017, 77
[39] Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) plus pemetrexed (pem) plus platinum (plt) for metastatic NSCLC.
Garassino, Marina Chiara
Rodriguez-Abreu, Delvys
Gadgeel, Shirish M.
Gonzalez, Emilio Esteban
Felip, Enriqueta
De Angelis, Flavia
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
Monk, Bradley J.
Colombo, Nicoletta
Tewari, Krishnansu Sujata
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
De Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Keefe, Stephen Michael
Lorusso, Domenica
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A420 - A420

← 1 2 3 4 5 →